Engaging Lung Disease Patients in FDA's Patient-Focused Drug Development Initiative

In April 2013, the U.S. Food and Drug Administration (FDA) announced it would be focusing on 16 diseases for the first phase of its Patient-Focused Drug Development Initiative (Initiative). Included in the Initiative are several important lung diseases including lung cancer and idiopathic pulmonary fibrosis.

On June 28, FDA held its meeting on lung cancer. The American Lung Association engaged directly with FDA in order to ensure FDA heard directly from lung cancer patients and caregivers about the symptoms and side effects lung cancer patients’ experience, the daily impacts on patients’ lives, and patient perspectives on current approaches to treatment. In August, the Lung Association submitted its comments as well as the results from a patient and caregiver survey it conducted.

In late December 2013, FDA issued its cumulative report, Voice of the Patient Report: Lung Cancer, which summarizes the patient comments and feedback received during this process – including the comments submitted by the American Lung Association.